Seattle Genetics Reports Fourth Quarter and Year 2013 Financial Results

[at noodls] – -Total 2013 Revenues of $269.3 Million, Including $144.7 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -Data Anticipated in 2014 from ADCETRIS Phase 3 AETHERA Trial and … more

View todays social media effects on SGEN

View the latest stocks trending across Twitter. Click to view dashboard

See who Seattle is hiring next, click here to view